Molecular analysis of gamma-globin promoters, HS-111 and 3'HS1, in beta-thalassemia intermedia patients associated with high levels of Hb F
- PMID: 19958188
- DOI: 10.3109/03630260903336479
Molecular analysis of gamma-globin promoters, HS-111 and 3'HS1, in beta-thalassemia intermedia patients associated with high levels of Hb F
Abstract
The nucleotide (nt) variations in the promoter region of the gamma-globin genes, HS-111 and 3'HS1 regions, were studied in Iranian patients with beta-thalassemia intermedia (beta-TI), beta-thalassemia major (beta-TM) and healthy individuals. Of the five nt variations at the 5' end of the (A)gamma-globin gene, -369 (C>G), -611 (-T) and -603/604 (GA>AG) were found in all samples, whereas -588 (A>G) and -AAGC at -222 to -225 were found at different frequencies in the studied groups. Therefore, the -369, -611 and -603/604 variations were considered common mutations in this population, and the difference with respect to the -AAGC deletion was not significant. However, the A allele of the -588 variation and [+] allele of the XmnI polymorphism were more frequent in beta-TI patients, especially those who had the IVS-II-1(G>A)/IVS-II-1(G>A) genotype. The + allele of XmnI also had complete correlation with the A allele of -588 variation. The HS-111 (-21 A) variation also showed association with beta-TI patients who had high levels of Hb F. Bearing in mind that the -588 variation lies within the postulated adult-specific silencer region and that the majority of beta-TI patients had allele A, then it can be envisaged that this allele could have a role in altering the repressor function at this region. Therefore, the A allele of -588, [+] allele of XmnI and HS-111 (-21 A) variation are useful genetic markers to differentiate between beta-TM and beta-TI patients. However, these nt changes alone may not be the only elements raising the level of Hb F, other regulatory and modifying factors also play a role in Hb F production.
Similar articles
-
Increased gamma-globin gene expression in beta-thalassemia intermedia patients correlates with a mutation in 3'HS1.Am J Hematol. 2007 Nov;82(11):1005-9. doi: 10.1002/ajh.20979. Am J Hematol. 2007. PMID: 17654503
-
[Beta-thalassemia mutations and single nucleotide polymorphism at -158 of Ggamma-globin gene associated with altered levels of Hb F in beta-thalassemia heterozygotes].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004 Oct;21(5):498-501. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004. PMID: 15476181 Chinese.
-
Homozygosity for a rare beta 0-thalassemia mutation [frameshift codons 25/26 (+T)] causes beta-thalassemia intermedia in an Iranian family.Hemoglobin. 2009;33(1):75-80. doi: 10.1080/03630260802683377. Hemoglobin. 2009. PMID: 19205978
-
Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.Pediatr Hematol Oncol. 2009 Nov;26(8):560-5. doi: 10.3109/08880010903271671. Pediatr Hematol Oncol. 2009. PMID: 19954365 Review.
-
Fetal globin induction in beta-thalassemia.Hemoglobin. 2009;33 Suppl 1:S197-203. doi: 10.3109/03630260903351882. Hemoglobin. 2009. PMID: 20001626 Review.
Cited by
-
Genetic research and clinical analysis of β-globin gene cluster deletions in the Chinese population of Fujian province: A 14-year single-center experience.J Clin Lab Anal. 2022 Feb;36(2):e24181. doi: 10.1002/jcla.24181. Epub 2021 Dec 23. J Clin Lab Anal. 2022. PMID: 34951062 Free PMC article.
-
Xmn1-158 γGVariant in B-Thalassemia Intermediate Patients in South-East of Iran.Int J Hematol Oncol Stem Cell Res. 2017 Apr 1;11(2):165-171. Int J Hematol Oncol Stem Cell Res. 2017. PMID: 28875012 Free PMC article.
-
Transient expression assay of Agamma-588 (A/G) mutations in the K562 cell line.Iran Biomed J. 2011;15(1-2):15-21. Iran Biomed J. 2011. PMID: 21725495 Free PMC article.
-
Genetic epidemiology, hematological and clinical features of hemoglobinopathies in Iran.Biomed Res Int. 2013;2013:803487. doi: 10.1155/2013/803487. Epub 2013 Jun 18. Biomed Res Int. 2013. PMID: 23853772 Free PMC article. Review.
-
Role of XmnIgG Polymorphism in Hydroxyurea Treatment and Fetal Hemoglobin Level at Isfahanian Intermediate β-Thalassemia Patients.Iran Biomed J. 2015;19(3):177-82. doi: 10.7508/ibj.2015.03.008. Epub 2015 May 30. Iran Biomed J. 2015. PMID: 26024726 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous